CARBOTRAP (Empagliflozin) 10 mg/ 25 mg Tablet


As per the latest information available, prediabetes and diabetes prevalence in Nepal is 9.2% and 8.5% respectively. Type-II diabetes is more common than Type-I. Only half of the patients with diabetes are aware of their diabetic status, and even fewer are taking antidiabetic medicines. Only a third of those under therapy have their blood glucose under control. There is higher risk of CV and renal complications in diabetic patients. For patients battling Type-II diabetes, Deurali-Janta introduces CARBOTRAP for protection beyond glycemic control. It’s the best quality Empagliflozin at lowest price in the market. Affordability, Accessibility, Commitment to the Consumers, Quality, and Reliability are the key values CARBOTRAP offers.


Go to this link to know more about this product.